Short answer
Wave Life Sciences Ltd. (WVE) filed an 8-K current report with the SEC on April 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Q1 2026 financial results announced for quarter ended March 31, 2026.
Wave Life Sciences Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results announced for quarter ended March 31, 2026
- Full results and management commentary available in furnished Exhibit 99.1
- Investor focus: quarterly performance details, liquidity, and development-program spending in the exhibit
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation released April 28, 2026, providing investors with refreshed business and pipeline information
- Presentation available on Wave Life Sciences’ investor website and furnished as Exhibit 99.2
- Reg FD disclosure is furnished, not filed, limiting Exchange Act Section 18 liability and automatic incorporation into registration statements
Item EX-99.1 · Exhibit EX-99.2
- Q1 2026 revenue $38.2M versus $9.2M, reducing net loss to $26.1M from $46.9M
- Cash $544.6M at March 31, 2026, supporting operations into 3Q 2028 without projected collaboration milestones
- WVE-007 Phase 2a obesity trial on track for 2Q 2026, targeting higher-BMI participants with and without type 2 diabetes
- WVE-006 data from 400 mg monthly and 600 mg single-dose cohorts expected May 18, with accelerated-approval feedback targeted mid-2026
- WVE-008 CTA filing and WVE-N531 NDA filing remain targeted for 2026, creating multiple regulatory catalysts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Wave Life Sciences Ltd. 8-K filings
Get the next WVE 8-K as it lands
Follow WVE for push alerts, or ask the research agent what this filing means.